Evidence map›Paper›PMID 33777430›Full record

ReviewSultan Qaboos University medical journal2021

Complications and Management of Totally Implantable Central Venous Access Ports in Cancer Patients at a University Hospital in Oman.

Philomena C D'Souza, Shiyam Kumar, Annupam Kakaria, Rashid Al-Sukaiti, Khalid Al-Baimani, Rana S Hamid, Alok K Mittal, Muna Al-Balushi, Ikram A Burney, Mansour S Al-Moundhri

Open access · diamondAbstract readReview
In one paragraph

Review in Sultan Qaboos University medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. [Surgical complications of totally implantable venous access port in children with malignant tumors].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Philomena C D'SouzaOncology Ward, Churchill Hospital, Oxford University Hospitals, Oxford, United Kingdom.
Shiyam KumarDepartment of Medical Oncology, Yeovil District Hospital, NHS Foundation Trust, Yeovil, United Kingdom.
Annupam KakariaDepartment of Radiology & Molecular Imaging, Sultan Qaboos University Hospital, Muscat, Oman.
Rashid Al-SukaitiDepartment of Radiology & Molecular Imaging, Sultan Qaboos University Hospital, Muscat, Oman.
Khalid Al-BaimaniDepartment of Radiology & Molecular Imaging, Sultan Qaboos University Hospital, Muscat, Oman.
Rana S HamidDepartment of Radiology & Molecular Imaging, Sultan Qaboos University Hospital, Muscat, Oman.
Alok K MittalDepartment of Radiology & Molecular Imaging, Sultan Qaboos University Hospital, Muscat, Oman.
Muna Al-BalushiNursing Directorate, Sultan Qaboos University Hospital, Muscat, Oman.
Ikram A BurneyDepartment of Medicine, Sultan Qaboos University Hospital, Muscat, Oman.
Mansour S Al-MoundhriDepartment of Medicine, Sultan Qaboos University Hospital, Muscat, Oman.
Sultan Qaboos University Hospital · OMChurchill Hospital · GBYeovil District Hospital NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTotally implantable central venous access ports (port-a-caths) are increasingly used for the safe administration of chemotherapy; however, their use is associated with complications. This study reviews patterns of complications, reasons for premature removal and the duration of the use of port-a-caths in patients receiving cancer treatment at Sultan Qaboos University Hospital (SQUH) and compares the infection rate with the literature and the researchers' experiences.

methodsThis retrospective follow-up study included patients who had received cancer treatment through a port-a-cath and were admitted to SQUH between January 2007 and April 2019. Demographic features, underlying diagnosis, clinical stage, treatment, duration of use and the cause of premature removal of the port-a-cath were recorded.

resultsA total of 516 port-a-caths were inserted in 482 cancer patients. The majority of devices were implanted by interventional radiologists (n = 459; 89.0%) and the right internal jugular vein was most frequently accessed (n = 396; 76.7%). The mean indwelling time of a port-a-cath was 288 days (range: 3-1,872 days) for patients with complications and 550 days (range: 7-3,123 days) for patients without complications. Port-a-cath-related infection was the main complication (n = 63; 12.2%). Patient age, gender, treatment intent, underlying diagnosis, clinical stage, chemotherapy regimen, number of treatment courses, operator implanting the port, the type of micro-organism isolated from the port-a-cath and body mass index were significant factors affecting catheter indwelling time (

conclusionInfection was the most common complication necessitating port-a-cath removal. The infection rate was much lower than the researchers' previous experience and compares favorably with several published reports.

Indexed as

Antineoplastic AgentsCatheterization, Central VenousCatheter-Related InfectionsFemaleFollow-Up StudiesHospitals, UniversityHumansJugular VeinsMaleNeoplasmsOmanProsthesis-Related InfectionsRetrospective StudiesSepsisVascular Access DevicesAntineoplastic AgentsCancerCatheter-Related InfectionsOmanPort-A-CathVascular Access Ports

Identifiers

PMID33777430
PMCPMC7968907
OpenAlexW3136717651

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.